The Department of Thoracic Medicine continues to pursue a diverse range of research from basic clinical and applied physiology to innovation in clinical care as well as answering practical questions that are important to the community. The Department is one of Australia's most active clinical laboratories with a focus on translational research while maintaining a strong focus on undergraduate and postgraduate education. In 2016 there were seven enrolled PhD candidates undertaking work wholly or partly within the Department with two students having graduated with their PhD in the course of 2016. Senior members of the Department have maintained a strong commitment with local and international professional societies and are regarded as experts in their field.
Our Department's research activities focus on five main streams; Airways physiology, cilia function, effects of hypoxia on cardio-respiratory function, sleep medicine, and interventional pulmonology. The laboratory is conducting a number of studies evaluating novel measures of airway function with a focus on translational research into small airway structure and function. We have been working with Fire and Rescue NSW to create a selection algorithm to determine which people with a history of asthma can safely be recruited to the service. Some of these studies are conducted in collaboration with the Woolcock Institute of Medical research and Sydney University. Other research collaborations in 2016 included the Concord Hospital Departments of Cardiology, Endocrinology and Nuclear Medicine, Macquarie University, University of Technology and Royal North Shore Hospital.
The Department continues to be active in a range of Clinical Trials, some funded by Industry and others via NH&MRC, that study the effects of new and novel therapeutic interventions for the treatment of asthma, interstitial lung disease, bronchiectasis and chronic obstructive pulmonary disease (COPD). There has been an expansion of clinical trial in interstitial lung disease associated with the development of new treatments.
Clinical care Initiatives
In keeping with a focus on improving patient care and clinically relevant research, the Department has developed sub-specialty clinics for airways Diseases (including asthma and COPD), bronchiectasis, primary ciliary dyskinesia, sleep medicine and a metabolic-respiratory failure clinic. Regular multidisciplinary meetings are also conducted for interstitial lung disease and lung cancer.
Our Department's research activities focus on five main streams; Airways physiology, cilia function, effects of hypoxia on cardio-respiratory function, sleep medicine, and interventional pulmonology. The laboratory is conducting a number of studies evaluating novel measures of airway function with a focus on translational research into small airway structure and function. These studies are conducted in collaboration with the Woolcock Institute of Medical research and Sydney University. Other research collaborations in 2016 included the Concord Hospital Departments of Cardiology, Endocrinology and Nuclear Medicine, Macquarie University, University of Tasmania, Adelaide University, University of Technology and Royal North Shore Hospital.
- Professor Peters: Past-President of the Thoracic Society of Australia and New Zealand Clinical
- Professor Christine Jenkins: Chair Australian Lung Foundation
- Clinical Associate Professor Rutland: President of NSW Branch of the TSANZ.
- Dr Claude Farah: Convenor of Special Interest Group - Physiology and Sleep Medicine TSANZ and co-convenor 'Flow Volume Underworld'
- Dr Leigh Seccombe: Director, Education and Professional Activity Portfolio, ANZSRS
- Dr Leigh Seccombe, Best Oral Presentation, ANZSRS ASM Perth
- Professor Matthew Peters
- Professor Christine Jenkins
- Professor Alvin Ing
- Professor Jonathon Rutland
- Dr Leon Laks
- Dr Ruby Brillante
- Professor Lucy Morgan
- Dr Elizabeth Veitch
- Dr Claude Farah
- Dr Tajalli Saghaie
- Dr Leigh Seccombe
- Ms Gavina Cossa
- Mr Lachlan Buddle
- Mr Peter Rogers
Higher Degree Students:
- Mrs Kerrie Wade
- Ms Tessa Bird
- Dr Kelvin Hsu
- Dr Stephen Milne
- Dr Katrina Tonga
- Ms Kanika Jetmalani
- Dr Sabine Zimmerman
- Ms Alesha Mitchell
- Dr Alice Cottee
- Mr Liam Acheson, Master of Medicine
Publications and Presentations
- Seccombe LM, Peters MJ, Brown RH, Mitzner W. Lung Density in Extremely Large Healthy Lungs. Chest 2016;149(1):291-2.
- Seccombe LM, Rogers PG, Buddle L, Karet B, Cossa G, Peters MJ, Veitch EM. The impact of severe lung disease on evidential breath analysis collection. Science and Justice 2016
- Watts JC, Farah CS, Seccombe LM, Handley BM, Schoeffel RE, Bertolin A, Dame Carroll J, King GG, Thamrin C. Measurement duration impacts variability but not impedance measured by the forced oscillation technique in health, asthma and COPD. ERJ Open Research DOI: 10.1183/ 23120541.00094-2015.
- Jetmalani K, Chapman DG, Thamrin C, Farah CS, Berend N, Salome CM, King GG. Bronchodilator responsiveness of peripheral airways in smokers with normal spirometry. Respirology 2016; in press
- Mailhot-Larouchea S, Tremblaya F, Poiriera M, Farah CS, Bossé Y. The contractile lability of smooth muscle in asthmatic airway hyperresponsiveness. Exp Rev Respir Med 2016; 10: 19-27
- B. Aliprandi-Costa, J. Sockler, L. Kritharides, L. Morgan, L. Snell, J. Gullick, D. Brieger, I. Ranasinghe The Contribution of the Composite of Clinical Process Indicators as a Measure of Hospital Performance in the Management of Acute Coronary Syndromes-insights from the CONCORDANCE Registry Eur Heart J Qual Care Clin Outcomes 2016 May 10
- Chalmers, J., Aliberti, S., Polverino, E., Vendrell, M., Crichton, M., Loebinger, M., Dimakou, K., Clifton, I., van der Eerden, M., Rohde, G., Murris-Espin, M., Masefield, S., Gerada, E., Shteinberg., M, Ringshausen, F., Haworth, C., Boersma, W., Rademacher, J., Hill, A., Aksamit, T., O'Donnell, A., Morgan, L., Milenkovic, B,, Tramma, L,, Neves, J,, Menendez, R,, Paggiaro, P,, Botnaru, V,, Skrgat, S., Wilson, R., Goeminne, P., De Soyza, A., Welte, T., Torres, A., Elborn, S., Blasi, F., on behalf of EMBARC. The EMBARC European Bronchiectasis Registry: protocol for an international observational study. European Respiratory Society Journals. ERJ Open ERJ Open Research Jan 2016, 2 (1) DOI: 10.1183/23120541.00081-2015
- Edwards, M., Brescianini, S., Allgood, C., Freelander, M., Dunstan, R., Patradoon-Ho, P., Chin, R., Morgan, L., Pervez, T., Legendre, M., Burgess, T., Amselem, S. and Whitehall, J. (2016), Syndrome diagnosis with single-nucleotide polymorphism (SNP) microarray. Journal of Paediatrics and Child Health, 52: 85-89. doi: 10.1111/jpc.12981
- Alison JA, McKeough ZJ, Jenkins SC, et al. A randomised controlled trial of supplemental oxygen versus medical air during exercise training in people with chronic obstructive pulmonary disease: supplemental oxygen in pulmonary rehabilitation trial (SuppORT) (Protocol). BMC pulmonary medicine 2016;16:25. doi: 10.1186/s12890-016-0186-4
- Peters MJ. Disruptive thinking: The virtue of challenging collective therapeutic intuition. Respirology. 2016; 21:207-8
- Simpson JL, Yang IA, Upham JW, Reynolds PN, Hodge S, James AL, Jenkins C, Peters MJ, Jia G, Holweg CT, Gibson PG. Periostin levels and eosinophilic inflammation in poorly-controlled asthma. BMC Pulm Med. 2016;16:67. doi: 10.1186/s12890-016-0230-4.
- Carbonnaux M, Souquet PJ, Meert AP, Scherpereel A, Peters M, Couraud S. Inequalities in lung cancer: a world of EGFR. Eur Respir J. 2016;47:1502-9.
- Aggarwal A, Lewison G, Idir S, Peters M, Aldige C, Boerckel W, Boyle P, Trimble EL, Roe P, Sethi T, Fox J, Sullivan R. The State of Lung Cancer Research: A Global Analysis. J Thorac Oncol. 2016 Mar 21. pii: S1556-0864(16)30020-X. doi: 10.1016/j.jtho.2016.03.010
- Hew M, Gillman A, Sutherland M, Wark P, Bowden J, Guo M, Reddel HK, Jenkins C, Marks GB, Thien F, Rimmer J, Katsoulotos GP, Cook M, Yang I, Katelaris C, Bowler S, Langton D, Wright C, Bint M, Yozghatlian V, Burgess S, Sivakumaran P, Yan KY, Kritikos V, Peters M, Baraket M, Aminazad A, Robinson P, Jaffe A, Powell H, Upham JW, McDonald VM, Gibson PG. Real-life effectiveness of omalizumab in severe allergic asthma above the recommended dosing range criteria. Clin Exp Allergy 2016 Jul 5. doi: 10.1111/cea.12774
- Gibson PG, Reddel H, McDonald VM, Marks G, Jenkins C, Gillman A, Upham J, Sutherland M, Rimmer J, Thien F, Katsoulotos GP, Cook M, Yang I, Katelaris C, Bowler S, Langton D, Robinson P, Wright C, Yozghatlian V, Burgess S, Sivakumaran P, Jaffe A, Bowden J, Wark PA, Yan KY, Kritikos V, Peters M, Hew M, Aminazad A, Bint M, Guo M. Effectiveness and response predictors of omalizumab in a severe allergic asthma population with a high prevalence of comorbidities: the Australian Xolair Registry. Intern Med J. 2016 Jun 28. doi: 10.1111/imj.13166
Contact details for department
Head of Department: Prof Matthew Peters
Department/Unit: Thoracic Medicine
Telephone: (02) 9767 6712
Facsimile: (02) 9767 6991